Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ready to take off?
Good news last week, but...why is CYTX going down?
ready to run up IMHO
$CYTX is ready to boost
CTYX: Chinese Approval of Regenerative Cell Technology
Chinese Approval of Regenerative Cell Technology
Cytori Therapeutics (CYTX) Stock Spikes Today on Chinese Approval of Regenerative Cell Technology
By Tony Owusu Follow | 04/06/15 - 01:19 PM EDT
NEW YORK (TheStreet) -- Cytori Therapeutics (CYTX - Get Report) shares are up 19.83% to $1.39 in afternoon trading on Monday after the company said that Chinese regulators approved its regenerative cell technology.
Lorem Vascular has the rights to market the treatment due to a 2013 deal between the two companies, which they said could be worth up to $500 million. Lorem plans to market the drug as a treatment for cardiovascular, renal conditions and diabetes, according to the Associated Press.
However, the companies were not specific on how much money Cytori will be receiving from Lorem as part of the deal. Questions about the specifics of their agreement have been swirling since the deal was signed in 2013.
TheStreet's Adam Feuerstein wrote about their pact in 2013, here.
TheStreet Ratings team rates CYTORI THERAPEUTICS INC as a Sell with a ratings score of D-. TheStreet Ratings Team has this to say about their recommendation:
"We rate CYTORI THERAPEUTICS INC (CYTX) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself."
Highlights from the analysis by TheStreet Ratings Team goes as follows:
CYTX's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 58.66%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
The company, on the basis of net income growth from the same quarter one year ago, has significantly underperformed compared to the Biotechnology industry average, but is greater than that of the S&P 500. The net income increased by 42.7% when compared to the same quarter one year prior, rising from -$10.04 million to -$5.76 million.
The gross profit margin for CYTORI THERAPEUTICS INC is rather high; currently it is at 69.17%. Despite the high profit margin, it has decreased significantly from the same period last year. Despite the mixed results of the gross profit margin, CYTX's net profit margin of -152.71% significantly underperformed when compared to the industry average.
Net operating cash flow has increased to -$4.96 million or 47.82% when compared to the same quarter last year. Despite an increase in cash flow, CYTORI THERAPEUTICS INC's average is still marginally south of the industry average growth rate of 49.59%.
CYTORI THERAPEUTICS INC has improved earnings per share by 42.9% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, CYTORI THERAPEUTICS INC reported poor results of -$0.49 versus -$0.38 in the prior year. This year, the market expects an improvement in earnings (-$0.28 versus -$0.49).
You can view the full analysis from the report here: CYTX Ratings Report
EKWX is ready to run
DARA & CYTX, ready to pop
DARA is ready to POP UP
CYTX is burning
green today ;)
ready to run the next leg up
$DNDNQ up in the air :)
$DNDNQ is a rocket
$DNDNDQ +37%... Run, Forrest! Run
Run, Forrest! Run!
Good luck tomorrow!
we are going to take off
$DNDNQ: fasten your seatbelts!
L2 is very thin. 0.21$ at EOD
$DNDNQ +20%, Huge! Great potential... tomorrow could be great
rush hour ?
Anybody knows the schedule of the auction?
when will we known any about the action and we will be payd?
$DNDNQ, ready to run the next leg up imho
When will the auction finish?
$DNDNQ...load the boad and ride thee MOMO
Alert $DNDNQ! Mega-runner... news about the action
.25$ today?
$DNDNQ really HOT +25%
$DNDNQ ALERT, breaking out!
guau! .18 +20%
moving up bro! running to .20
ready to fly!
green today
Valeant Pharmaceuticals Inc. set a $296 million floor price for the prostate cancer drug
trades at 0.23?
4000 (seq) at 10:17:56
2000 (seq) at 10:21:41
5000 (seq) at 10:23:07
5000 (seq) at 10:24:53
back to green, don't be afraid
Please, Real Time